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Abstract
Background: Immunocompromised patients who develop sepsis while neutropenic are at high risk for morbidity
and mortality; however, it is unknown if neutropenic sepsis is associated with distinct clinical and biological
characteristics.
Methods: We conducted a prospective cohort study of patients admitted to the medical intensive care unit of an
academic medical center with severe sepsis. Patients were followed for the development of acute respiratory
distress syndrome (ARDS), acute kidney injury (AKI), and mortality. Plasma proteins, representing the host
inflammatory response, anti-inflammatory response, and endothelial leak were measured in 30 % of subjects.
Clinical characteristics and plasma protein concentrations of patients with neutropenia at enrollment were
compared to patients without neutropenia.
Results: Of 797 subjects enrolled, 103 (13 %) were neutropenic at ICU admission. The neutropenic subjects were
more often in shock, admitted from the hospital ward, had higher APACHE III scores, and more likely bacteremic.
Neutropenia was an independent risk factor for AKI (RR 1.28; 95 % CI 1.04, 1.57; p = 0.03), but not ARDS (RR 0.90;
95 % CI 0.70, 1.17; p = 0.42) or 30-day mortality (RR 1.05; 95 % CI 0.85, 1.31; p = 0.65). Neutropenic subjects had
higher plasma interleukin (IL)-6 (457 vs. 249 pg/ml; p = 0.03), IL-8 (581 vs. 94 pg/ml; p <0.001), and granulocyte
colony-stimulating factor (G-CSF) (3624 vs. 99 pg/ml; p <0.001). Angiopoietin-2 and IL-1 receptor antagonist
concentrations did not differ between groups.
Conclusions: Neutropenic sepsis is associated with a higher AKI risk and concentrations of inflammatory mediators
IL-6, IL-8, and G-CSF relative to non-neutropenic patients. These differences may have implications for future
therapies targeting neutropenic sepsis.
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Background
The incidence of severe sepsis is increasing among
hospitalized patients in the developed world [1, 2], while
therapeutic options beyond supportive care remain
limited [3, 4]. Currently, sepsis is the leading cause of
death in non-cardiac intensive care units (ICUs) [5]. The
host response to systemic infection is heterogeneous,
influenced by clinical and molecular factors, resulting in
variability in the pathogenic processes of sepsis and
its outcomes. Immunocompromise caused by cancer,
immunodeficiency, or immunosuppressing therapy is
increasingly common in ICUs and is a strong contributor
to sepsis risk [6]. Furthermore, immunocompromised
states are associated with lower sepsis survival [7],
with neutropenia being a particularly high-risk condition
for critically ill patients with sepsis [8]. As the neutrophil
is believed to have a central role in the pathogenesis of
sepsis and related organ dysfunction [9, 10], understand-
ing whether neutropenic patients with sepsis demonstrate
distinct clinical or molecular characteristics is an import-
ant yet unanswered question.
In this single-center prospective cohort study of critic-
ally ill subjects with severe sepsis, we sought to deter-
mine if neutropenia is associated with distinct clinical
and biological factors compared to patients without neu-
tropenia, as heterogeneity in host response to infection
is likely a strong determinant of sepsis risk, mortality,
and potentially response to experimental therapy. To ac-
complish this objective, we examined clinical character-
istics, outcomes, and plasma biomarker profiles among
neutropenic and non-neutropenic subjects with severe
sepsis. We selected plasma biomarkers, measured at ICU
admission, known to be associated with sepsis outcomes,
including interleukin (IL)-6, IL-8, granulocyte colony-
stimulating factor (G-CSF), angiopoietin-2 (ANG2), and
IL-1 receptor antagonist (IL1RA). IL-6 and IL-8 are in-
flammatory markers most strongly associated with sever-
ity of sepsis and death [11–13]. Plasma G-CSF partially
regulates IL-8 and IL-6 production and is an important
stimulating factor for granulocyte production [14, 15].
ANG2 is a marker of activated endothelium, results in
increased vascular permeability [16], and is associated
with sepsis severity, shock, organ dysfunction, and
death [17–19]. Plasma interleukin-1 receptor antagonist
(IL1RA) is an inhibitory anti-inflammatory cytokine
that antagonizes the proinflammatory effects of IL-1
alpha and beta at the IL-1 receptor and has been asso-
ciated with septic shock, acute respiratory distress
syndrome (ARDS), and multi-organ failure [20, 21].
By measuring these select plasma proteins, we aimed
to characterize the relative contributions of inflamma-
tory/anti-inflammatory signaling and endothelial perme-
ability to neutropenic sepsis. If neutropenic sepsis is
associated with distinct clinical or biological variables, this
knowledge should inform future tests of emerging preci-
sion medicine options in this population [22].
Methods
Study population
Patients presenting to the medical ICU at the Hospital of
the University of Pennsylvania, a large urban tertiary-care
referral center with active cancer, solid organ transplant,
and bone marrow transplant programs, were screened for
sepsis. Patients who met the American College of Chest
Physicians/Society of Critical Care Medicine consensus
criteria for severe sepsis or septic shock [23] were eligible
for participation in the Molecular Epidemiology of Severe
Sepsis in the ICU (MESSI) cohort study if infection-
related organ dysfunction was deemed the primary cause
for ICU admission [24]. Patients were excluded for lack of
commitment to life support at the time of ICU admission,
previous enrollment in MESSI, or admission from a
long-term care facility. All patients enrolled from cohort
initiation in September 2008 until February 2013 were
included in the current study. The Institutional Review
Board of the University of Pennsylvania approved the
study with a waiver of timely informed consent. Informed
consent was subsequently obtained from subjects or their
proxies, who could withdraw at any time.
Data collection
Clinical and laboratory data of prospectively enrolled
subjects were collected from the electronic medical record
by trained research personnel, using structured case
report forms. Data collected included baseline demo-
graphics, chronic health information, and physiologic, mi-
crobiologic, and laboratory data. Race was self-reported by
the patient or proxy.
Exposure and outcome definitions
Neutropenia was defined as an absolute neutrophil count
(ANC = polymorphonuclear leukocytes + band forms) less
than 1000/microliter on manual or automated differential
on the day of ICU admission in the presence of an immu-
nocompromising condition [25]. Immunocompromising
conditions included solid malignancies with recent cyto-
toxic medication administration, hematologic malignancies
(i.e., leukemia, lymphoma, or myeloma) including individ-
uals who had undergone hematopoietic stem cell trans-
plantation, the acquired immune deficiency syndrome
(AIDS), solid organ transplantation, conditions result-
ing in bone marrow failure including aplastic anemia,
primary or congenital immunodeficiency, or use of
cytotoxic medications for a chronic condition, such as a
rheumatologic disease. In order to ensure that neutro-
penia predated sepsis and was not the result of sepsis,
we excluded patients without a known or subsequently
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diagnosed immunocompromising condition who were
neutropenic on ICU presentation.
Patients were followed for 6 days after ICU admission
for the development of organ dysfunction, specifically,
ARDS and acute kidney injury (AKI). ARDS was defined
in accordance with the Berlin definition with the added
requirement of invasive mechanical ventilation [26].
Arterial blood gases were obtained from the medical rec-
ord and chest radiographs were interpreted by two phys-
ician investigators (JPR, NJM), trained in standardized
interpretation for ARDS. Acute kidney injury (AKI) was
determined by Acute Kidney Injury Network (AKIN) cre-
atinine and renal replacement therapy consensus criteria
[27], using all creatinines ordered for clinical purposes
over the first 6 days of ICU admission. Mortality was de-
fined at 30 and 60 days.
Plasma collection and analysis
Enzyme-linked immunosorbent assays (ELISA) were per-
formed on citrated plasma drawn on the day of ICU ad-
mission. ELISA analyses were performed on 245 subjects
(30 %) due to limitations of plasma volume, availability,
and cost. The following plasma proteins were measured
individually by commercially available ELISA kits opti-
mized for human plasma: IL-8, IL-6, ANG2, G-CSF, and
IL1RA (R&D Systems, Minneapolis, MN, USA). Please
see online supplement (Additional file 1: Table S1) for
limits of detection, observed range, and intra-individual
coefficients of variation for each analyte.
Statistical analysis
Clinical characteristics were compared between neutro-
penic and non-neutropenic patients using the Pearson’s
chi-square or Fisher’s exact test for categorical data and
the Student’s t or Wilcoxon rank-sum test for continu-
ous data. Plasma protein concentrations were compared
using the Wilcoxon rank-sum test, and additional ana-
lyses were conducted stratified by ICU admission source.
We also tested for an association between neutropenia
at ICU admission and ARDS, AKI, and mortality using
multivariable logistic regression. Possible confounders
associated with the exposure or outcome with p <0.20 were
considered for inclusion in adjusted models, including se-
verity of illness as measured by the Acute Physiology and
Chronic Health Evaluation III (APACHE III) score. In ad-
justed analyses, the white blood cell count and immuno-
compromising condition components of the APACHE III
score were removed as these variables help define the ex-
posure (neutropenia). Additionally, blood gas components
and renal components were removed from APACHE III in
adjusted analyses for the outcomes ARDS and AKI, re-
spectively. Based on a final sample size of 794 subjects and
an expected incidence of ARDS, AKI, and mortality of
40 %, we estimated we would have 80 % power to detect a
15 % absolute difference in outcomes. Spearman correl-
ation coefficients were calculated to test for co-linearity of
plasma analyte pairs. Additionally, sensitivity analyses were
performed including only non-neutropenic patients with
an immunocompromising condition as the comparison
group. Sensitivity analyses were also conducted considering
immunocompromising condition as the exposure variable
rather than neutropenia to assess whether clinical or bio-
marker differences were attributable to neutropenia or
immunocompromise. All analyses were performed in Stata
v.12 (StataCorp, College Station, TX, USA).
Results
Clinical characteristics
The MESSI cohort enrolled 797 critically ill subjects
with severe sepsis or septic shock over the enrollment
period, 103 (13 %) of who were categorized as neutropenic
at ICU admission (Fig. 1). The septic subjects had a mean
age of 60 +/− 16 and APACHE III score of 77 +/− 24.
Forty-three percent were female, with a race distribution
of 57 % white, 34 % black, and 2 % Asian. Septic shock
was present in 62 % of subjects, and pneumonia was the
most common source of sepsis (42 %). Three neutropenic
subjects did not possess a predisposing immunocompro-
mising condition, had transient neutropenia (<24 hours),
and were removed from all further analyses. Among
the neutropenic subjects, the immunocompromising
condition was most commonly a hematologic malignancy
(n = 74, 74 %), followed by a solid malignancy (n = 14,
14 %), aplastic anemia (n = 4, 4 %), solid organ transplant-
ation (n = 3, 3 %), a rheumatologic condition (n = 1, 1 %,
granulomatosis with polyangiitis), and AIDS (n = 1, 1 %).
Three subjects (3 %) had more than one immuno-
compromising condition, including two subjects with
6,695 ED and ICU patients screened 
797 subjects enrolled in MESSI cohort
(103 neutropenic , 694 non-neutropenic )
Excluded: 5,898
Failed inclusion (i.e. not severe sepsis): 5,039
Met exclusion criteria: 262
Declined consent: 230
Not admitted to ICU: 367
3 Neutropenic subjects without 
immunocompromising condition. 
794 subjects enrolled in final cohort
(100 neutropenic , 694 non-neutropenic )
245 subjects with plasma testing
(29 neutropenic , 216 non-neutropenic )
Fig. 1 Screening and enrollment. ED emergency department, ICU
intensive care unit, MESSI Molecular Epidemiology of Severe Sepsis
in the ICU
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solid malignancies and treatment-related acute myeloid
leukemia, and one subject with AIDS and lung cancer.
The median ANC at enrollment for neutropenic subjects
was 44 (IQR, 0–295) cells per microliter and for non-
neutropenic subjects was 10,510 (IQR, 6225–16,025) cells
per microliter.
Compared to patients without neutropenia, the neu-
tropenic subjects were slightly younger with a higher se-
verity of illness, more often Caucasian, more likely to
have bacteremia, more often admitted from the hospital
ward rather than the emergency department (ED), more
likely to have a blood or vascular source of infection
(e.g., catheter-related bloodstream infection), and more
likely to be in shock on admission to the ICU (Table 1).
Neutropenic patients were less likely to have diabetes,
chronic kidney disease, congestive heart failure, or chronic
liver disease. Neutropenic subjects were significantly more
likely to develop AKI (58 % vs. 28 %, p <0.01) and had a
significantly higher mortality at 30 days (53 % vs. 41 %,
p = 0.02) (Table 1); however, after adjustment for con-
founders including severity of illness and admission
source, neutropenia was independently associated with
AKI but not mortality (Table 2). The risk of incident
ARDS within 6 days of ICU admission for sepsis was
not significantly different between groups in adjusted
or unadjusted analyses (Tables 1 and 2). Analyses limiting
the control group to patients with an immunocompromis-
ing condition (n = 252 in the non-neutropenic group)
did not significantly alter any results (Additional file 1:
Table S2 and Table S3). Possessing an immunocompro-
mising condition alone was not associated with ARDS
or AKI, but was associated with increased mortality
(Additional file 1: Table S4).
Plasma protein analysis
Characteristics of the 245 subjects with plasma protein
testing (Additional file 1: Table S5) were largely similar
to the overall cohort but with slightly lower severity of
illness and mortality than the overall population, par-
ticularly among the neutropenic plasma subpopulation.
Plasma concentrations of IL-6, IL-8, IL1RA, ANG2, and
G-CSF are shown in Table 3 stratified by neutropenic
status. Subjects with neutropenia had significantly higher
plasma IL-6 and IL-8 levels than non-neutropenic sub-
jects (Fig. 2a-b). Plasma IL1RA and ANG2 levels did not
vary by neutropenic status (Fig. 2d-e). Because both IL-8
and, to a lesser extent, IL-6 are regulated by G-CSF, we
measured G-CSF to contextualize the very high IL-8
levels. Plasma G-CSF concentrations were significantly
higher in neutropenic subjects (Fig. 2c). Additionally,
G-CSF demonstrated strong correlations with IL-8
(ρ = 0.55, p <0.001) and IL-6 (ρ = 0.46, p <0.001). Of
the 245 subjects with plasma protein measurements, 20
received exogenous G-CSF (filgrastim or pegfilgrastim)
within the prior 30 days (16 neutropenic patients and 4
non-neutropenic). Exogenous G-CSF was associated with
higher levels of IL-8 (p <0.001) and G-CSF (p <0.001), but
not the other measured analytes. Excluding these 20
subjects from analyses did not change any of the identified
associations between neutropenia and plasma protein
concentration (Table 3). Analyses limiting the control
group only to non-neutropenic subjects with an immuno-
compromising condition demonstrated similar results
(Additional file 1: Table S6). Biomarker concentrations did
not differ between immunocompromised patients and
non-immunocompromised (Additional file 1: Table S7).
Stratified analyses by ICU admission source (i.e., ED,
hospital ward, or outside hospital transfer) also demon-
strated similar associations between plasma proteins and
neutropenia.
Discussion
Our study provides evidence that neutropenic sepsis is
associated with distinct clinical and molecular factors
compared to non-neutropenic sepsis. These findings
suggest differences in underlying sepsis pathogenesis,
which may require targeted therapies particular to this
patient population. Specifically, neutropenic patients
with severe sepsis were more likely to present to the
ICU in shock and were more likely to have documented
bacteremia. Neutropenia at presentation to the ICU was
independently associated with a higher risk of AKI, but
not 30-day mortality or ARDS within 6 days of ICU ad-
mission after adjustment for clinical confounders. Neu-
tropenic patients also displayed higher levels of the
inflammatory cytokines IL-6 and IL-8 despite having
lower circulating immune cells. Our results support the
hypothesis that the pathogenesis of sepsis and related
organ dysfunction is different in neutropenic patients, as
well as the conclusion that traditional biomarkers of sep-
sis risk and prognosis may not perform equally in neu-
tropenic and non-neutropenic populations.
Our findings of higher IL-8, IL-6, and G-CSF among
neutropenic subjects are consistent with the current
knowledge of regulated neutrophil homeostasis, and sug-
gest that the elevations represent a physiologic state
whereby tissues are signaling for neutrophil recruitment
to fight infection. IL-8 is a neutrophil chemotactic factor
[28, 29], while IL-6 stimulates neutrophil production
[30, 31]. Typically antigen-presenting cells phagocytose
senescent neutrophils and downregulate further granulo-
poiesis [29]. The lack of senescent neutrophils in neutro-
penic patients circumvents this feedback inhibition
regulating neutrophil balance. This may result in con-
sistently high levels of G-CSF, and subsequently IL-8
and IL-6, in neutropenic subjects. Consistent with this
paradigm, we observed strong correlation of G-CSF with
IL-8 and IL-6 in our subjects. It is unclear whether
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Table 1 Patient characteristics by neutropenia statusa
Patient characteristic Non-neutropenic (n = 694) Neutropenic (n = 100) pb
Age 60 ± 16 58 ± 12 0.08
Male sex 387 (56 %) 66 (66 %) 0.06
Race
White 380 (55 %) 73 (73 %) <0.01
Black 255 (37 %) 17 (17 %)
Asian 19 (3 %) 0 (0 %)
Other/unknown 40 (6 %) 10 (10 %)
APACHE III 74 (59–90) 87 (71–109) <0.01
Documented bacteremia 182 (26 %) 43 (43 %) <0.01
Source of infection
Pulmonary 289 (42 %) 40 (40 %) 0.05
Genitourinary 82 (12 %) 6 (6 %)
Abdominal/gastrointestinal 93 (13 %) 15 (15 %)
Head/neck 17 (2 %) 0 (0 %)
Bloodc 58 (8 %) 15 (15 %)
Skin/soft tissue/bone 40 (6 %) 2 (2 %)
Gynecologic 2 (0 %) 0 (0 %)
Unclear source 113 (16 %) 22 (22 %)
Shock at presentation 371 (53 %) 74 (74 %) <0.01
Aminoglycoside exposure 182 (26 %) 65 (67 %) <0.01
IV contrast exposure 143 (21 %) 23 (23 %) 0.97
ICU admitting source
Emergency department 436 (63 %) 33 (33 %) <0.01
Hospital ward 200 (29 %) 64 (64 %)
Other institution 58 (8 %) 3 (3 %)
Comorbidities
Lymphoma 45 (6 %) 13 (13 %) 0.02
Leukemia 33 (5 %) 52 (52 %) <0.01
Multiple myeloma 21 (3 %) 10 (10 %) <0.01
Solid malignancy 82 (12 %) 16 (16 %) 0.24
Solid organ transplant 50 (7 %) 3 (3 %) 0.08
AIDS 11 (2 %) 2 (2 %) 0.67
Diabetes 225 (32 %) 19 (19 %) <0.01
Chronic renal disease 119 (17 %) 9 (9 %) 0.04
Congestive heart failure 107 (15 %) 6 (6 %) 0.01
Chronic liver disease 81 (12 %) 2 (2 %) <0.01
Outcomes
ARDSd 267 (38 %) 42 (42 %) 0.51
AKId 263 (38 %) 58 (58 %) <0.01
30-day mortality 285 (41 %) 53 (53 %) 0.02
60-day mortality 311 (45 %) 60 (60 %) <0.01
APACHE Acute Physiology and Chronic Health Evaluation, IV intravenous, ICU intensive care unit, AIDS acquired immune deficiency syndrome, ARDS acute
respiratory distress syndrome, AKI acute kidney injury
aData are shown as n (%) for categorical variables, mean ± standard deviation for normally distributed continuous variables, and median (interquartile range) for
non-normally distributed continuous variables
bNormally distributed continuous variables were compared using the Student’s t test, non-normally distributed continuous variables using the Wilcoxon rank-sum
test, and categorical variables using a Pearson chi-square test or Fisher’s exact test
cBlood source of infection included catheter-related blood stream infections, endocarditis, and thrombophlebitis
dPatients were followed for the outcomes ARDS and AKI over the first 6 days of ICU admission
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elevated G-CSF, IL-8, and IL-6 contribute to the organ
dysfunction or increased shock observed in neutropenic
sepsis, but these elevations in inflammatory mediators
may be maladaptive. Both IL-8 and IL-6 are strongly as-
sociated with mortality, AKI, and ARDS in observational
studies of sepsis [11–13, 32–34]. IL-6-deficient mice are
resistant to AKI in ischemia-reperfusion and nephro-
toxin models [35, 36], suggesting IL-6 may have toxic
effects on the kidney. Interleukin-8 and its receptors
have likewise been suggested to mediate kidney injury
in an inflammatory model [37]. Further mechanistic
investigation is warranted to test whether high IL-8
and IL-6 levels can mediate kidney injury in the setting of
neutropenia, and explain our findings of increased AKI
risk among neutropenic patients with sepsis. Alternatively,
neutropenic patients may be exposed to more nephrotoxic
drugs, including aminoglycosides and/or chemotherapeu-
tics, proceeding or concurrent with sepsis, and the com-
bination of these insults may have predisposed to AKI.
The risk of ARDS within 6 days of ICU admission was
similar among the neutropenic and non-neutropenic
patients, despite a higher proportion with shock among
the neutropenic subjects. The neutrophil is believed to
be important early in ARDS pathogenesis, and its ab-
sence may protect the lung from injury. Kangelaris
and colleagues demonstrated increased expression of
neutrophil-related genes dominating the whole blood
expression pattern of patients with sepsis and ARDS at
ICU admission relative to those with sepsis and no ARDS,
supporting the importance of neutrophils early in ARDS
[38]. However, ARDS has been well described in neutro-
penic hosts and was present in 42 neutropenic subjects
enrolled in our study, suggesting heterogeneity in ARDS
pathogenesis based on the presence or absence of circulat-
ing neutrophils [39]. Monocyte and alveolar macrophage
deactivation in the setting of septic neutropenic ARDS
has been described as one mechanism of neutrophil-
independent lung injury [40, 41].
While not detected in our study, as the large majority
of our subjects were consistently neutropenic during the
study period; several previous studies have reported as-
sociations between recovery of peripheral neutrophil
counts and the onset or deterioration of ARDS [42–45].
Taken in the context of these previous reports, our
Table 2 Associations of neutropenia with acute respiratory distress syndrome risk, acute kidney injury risk, and mortality
Standardized risk, % (95 % CI)a
Outcomes Neutropenic Non-neutropenic Unadjusted RRb (95 % CI) p Adjusted RRb (95 % CI) p
ARDSc 36 % (27, 44 %) 40 % (36, 43 %) 1.09 (0.85, 1.40) 0.51 0.90 (0.70, 1.17) 0.42
AKId 54 % (44, 64 %) 42 % (38, 46 %) 1.39 (1.15, 1.69) 0.002 1.28 (1.04, 1.57) 0.03
30-day mortalitye 44 % (36, 53 %) 42 % (39, 46 %) 1.29 (1.05, 1.58) 0.03 1.05 (0.85, 1.31) 0.65
60-day mortalitye 52 % (43, 61 %) 46 % (43, 49 %) 1.34 (1.12, 1.60) 0.004 1.13 (0.93, 1.37) 0.23
CI confidence interval, RR relative risk, ARDS acute respiratory distress syndrome, AKI acute kidney injury, APACHE acute physiology and chronic health evaluation
aStandardized risks and 95 % confidence intervals by neutropenic status were determined using post-estimation marginal analyses of adjusted multivariable
logistic regression models
bRR and 95 % confidence intervals were estimated using post-estimation marginal analyses of logistic regression models
cFinal ARDS logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of chronic renal insufficiency, history of chronic
liver disease, and APACHE III without immunocompromising conditions, white blood cell, and arterial blood gas components
dFinal AKI logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of diabetes mellitus, history of congestive heart
failure, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions, white blood cell, and
renal components
eFinal mortality logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of diabetes mellitus, history of congestive
heart failure, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions and white blood
cell components
Table 3 Plasma protein concentrations by neutropenia statusa
Total population No exogenous G-CSFb
Plasma protein Non-neutropenic
(n = 216)





ANG2 (pg/ml) 8242 (4039, 16694) 9165 (2708, 17244) 0.65 8252 (3918, 16694) 9475 (3168, 18936 0.68
IL1RA (pg/ml) 1269 (243, 5202) 1049 (103, 5329) 0.77 1346 (249, 3205) 534 (198, 3717) 0.52
IL-6 (pg/ml) 249 (76, 752) 457 (181, 1117) 0.03 249 (75, 773) 457 (281, 1117) 0.11
IL-8 (pg/ml) 94 (27, 600) 581 (358, 1576) <0.01 93 (27, 600) 478 (361, 1681) <0.01
G-CSF (pg/ml) 99 (29, 474) 3624 (919, 10099) <0.01 90 (33, 331) 6660 (3411, 9045) <0.01
G-CSF granulocyte colony-stimulating factor, ANG2 angiopoietin 2, IL1RA interleukin-1 receptor antagonist, IL-6 interleukin-6, IL-8 interleukin-8
aData are displayed as median (interquartile range)
bExcluding subjects who received exogenous G-CSF within 30 days of enrollment
cPlasma protein levels were compared between neutropenic and non-neutropenic using the Wilcoxon rank-sum test
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findings of elevated IL-6, IL-8, and G-CSF in the setting
of neutropenic sepsis suggest that the neutropenic host
is primed to rapidly recruit neutrophils from the bone
marrow to the peripheral tissues upon count recovery.
Younger neutrophils are preferentially sequestered in the
pulmonary circulation and may be more likely to con-
tribute to endothelial damage than older neutrophils
[46]. Therefore, the rapid recruitment of neutrophils to
the lung may be maladaptive in the setting of recovery
from prolonged neutropenia. Future therapies could po-
tentially target the marked elevations in IL-6 and IL-8,
limiting neutrophil recruitment and subsequent lung in-
jury in patients predictably recovering from neutropenia,
such as those undergoing cytotoxic chemotherapy.
Our study has several important limitations. The MESSI
cohort was derived from a single-center, tertiary-care hos-
pital with an active bone marrow transplant program;
therefore, generalizability may be limited to similar popu-
lations. We followed patients for the first 6 days of their
ICU stay in order to capture ARDS and AKI related to the
initial septic episode; however, may have missed ARDS
that developed later in the ICU stay, including during
neutropenia recovery. Additionally, we may have been
underpowered to detect important associations between
neutropenia and clinical outcomes. Negative results should
be interpreted with caution. The plasma analysis was
limited to only 30 % of the cohort, limiting power to de-
tect potential important associations. However, despite
this limitation, ours is among the largest multi-marker
studies of patients with sepsis, with larger studies typically
employing multiplex arrays [47]. Furthermore, we identi-
fied several potentially important plasma proteins that dif-
fer between neutropenic and non-neutropenic sepsis. We
focused our plasma analysis on proteins we hypothesized
to be important in differentiating neutropenic and
non-neutropenic sepsis, but did not measure mediators of
systemic coagulation, cellular adhesion, or markers of epi-






Fig. 2 Box and whisker plots comparing plasma (a) IL-6, (b) IL-8, (c) G-CSF, (d) ANG2, and (e) IL1RA concentration between neutropenic patients
and non-neutropenic patients. IL interleukin, G-CSF granulocyte colony-stimulating factor, ANG2 angiopoietin 2, IL1RA interleukin-1
receptor antagonist
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that these pathways also contribute to neutropenic sepsis.
Lastly, our exposure definition relied solely on a periph-
eral white blood cell count and differential measured at
ICU admission, and may not reflect immune cells located
peripherally in tissues, or changes in neutrophil count
over time, although the majority of our neutropenic sub-
jects were neutropenic for the entire 6 days of ICU
observation.
Conclusions
In conclusion, our data support the hypothesis that se-
vere sepsis results in a distinct inflammatory response in
patients with neutropenia relative to those without neu-
tropenia. Neutropenia was independently associated with
a higher AKI risk and was characterized by a profile of
high IL-6, IL-8, and G-CSF relative to non-neutropenic
sepsis. These findings may have implications toward the
development of future sepsis and organ dysfunction
therapeutics targeting the neutropenic population.
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